Lakefront Biotherapeutics (LKFT) Cash from Investing Activities (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash from Investing Activities for 11 consecutive years, with $72.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 19.23% year-over-year to $72.0 million; the TTM figure through Mar 2026 stood at $318.7 million (up 15.22% YoY), while the FY2025 annual figure was $336.2 million, up 42.62% from the prior year.
• Cash from Investing Activities eased to $72.0 million in Q1 2026 per LKFT's latest filing, from $84.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $89.1 million in Q1 2025 and bottomed at -$1.0 billion in Q1 2022.
• Historically, Cash from Investing Activities has averaged -$100.7 million across 5 years, with a median of $72.0 million in 2026.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities surged 344.92% — and 2026, when it decreased 19.23%.
• Lakefront Biotherapeutics' Cash from Investing Activities stood at $18.5 million in 2022, then soared by 344.92% to $82.2 million in 2023, then slipped by 11.14% to $73.0 million in 2024, then climbed by 15.73% to $84.5 million in 2025, then retreated by 14.83% to $72.0 million in 2026.
• Business Quant data shows LKFT's Cash from Investing Activities at $72.0 million in Q1 2026, $84.5 million in Q4 2025, and $89.1 million in Q1 2025.